HighVista Strategies’s Immuneering IMRX Stock Holding History

HighVista Strategies’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-254,513	Closed	-$736K	–	144
2024 Q1	$736K	Hold	254,513	–	–	0.26%	105
2023 Q4	$1.87M	Hold	254,513	–	–	0.68%	49
2023 Q3	$1.95M	Buy	254,513 +1,403	+0.6%	+$12.9K	0.9%	34
2023 Q2	$2.57M	Buy	+253,110	New	+$2.43M	1.17%	26

Other funds holding IMRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HighVista Strategies's IMRX Position: Q2 2024 in Review

HighVista Strategies sold out of Immuneering (IMRX) in Q2 2024, closing a stake of 254,513 shares — an estimated $736K sold.

HighVista Strategies first reported a position in IMRX in Q2 2023 and held it in 4 quarters. The position peaked at $2.57M in Q2 2023. 59 funds tracked by Wall St. Rank hold IMRX as of Q2 2024.

HighVista Strategies reported no remaining Immuneering position as of Q2 2024 after selling out during the quarter.
HighVista Strategies sold 254,513 Immuneering shares in Q2 2024, an estimated $736K.
HighVista Strategies first reported a position in Immuneering in Q2 2023 and held it in 4 quarters.
HighVista Strategies's Immuneering position peaked at $2.57M in Q2 2023.
59 funds tracked by Wall St. Rank held Immuneering as of Q2 2024.

Based on HighVista Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.